The FDA said it warned Stemell Inc., of San Juan Capistrano, Calif., and its president and CEO, Peyman Taeidi, for manufacturing and distributing the unapproved products StemL UCB-Plus and StemL UCT-Plus, derived from umbilical cord and umbilical cord blood, and for deviating from current good tissue practice and good manufacturing practice requirements, including deficient donor eligibility practices and environmental monitoring.